Orion Group's Financial Statement documents for 2014 have been published. The documents are available in Finnish and English on the Company's website at http://www.orion.fi/en.
The official financial statement documents, which include the financial statements, the report of the Board of Directors and the auditor's report are available in Finnish at http://www.orion.fi/en/agm2015/.
Orion's Corporate Governance Statement for year 2014, adopted by the Board of Directors, is published as a separate report in Finnish and English on the Company's website at http://www.orion.fi/en.
Orion Corporation
| Olli Huotari SVP, Corporate Functions | Terhi Ormio VP, Communications |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2014 amounted to EUR 1,015 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.